AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36339368 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents
Number of subjects: 1450
Study 36339368 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stents
Number of subjects: 1450
Study 36339368 — intervention group
Group type: COMPARATOR
Intervention: First-generation sirolimus-eluting stents (SES)
Number of subjects: 1450
Study 36339520 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification and cognitive control training
Number of subjects: 32
Study 36339520 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 36339533 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound methyl salicylate liniment (Ammeltz)
Number of subjects: 3600
Study 36339707 — intervention group
Group type: EXPERIMENTAL
Intervention: Special mountain spa rehabilitation program
Number of subjects: 0
Study 36339707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of spa rehabilitation with ubiquinol therapy
Number of subjects: 0
Study 36339849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime PTSD diagnosis
Number of subjects: 79
Study 36339849 — intervention group
Group type: COMPARATOR
Intervention: History of trauma
Number of subjects: 79
Study 36339849 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 79
Study 36339849 — intervention group
Group type: COMPARATOR
Intervention: Non-PTSD group
Number of subjects: 79
Study 36339926 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib, a selective MET inhibitor
Number of subjects: 66
Study 36339926 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib
Number of subjects: 66
Study 36340254 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 600
Study 36340254 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 600
Study 36340254 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PCI and CABG
Number of subjects: 600
Study 36340699 — intervention group
Group type: EXPERIMENTAL
Intervention: GUARDIAN socio-technical platform (including Caregiver App, Senior App, and Misty II robot)
Number of subjects: 0
Study 36340699 — intervention group
Group type: EXPERIMENTAL
Intervention: GUARDIAN socio-technical platform
Number of subjects: 0
Study 36341220 — intervention group
Group type: EXPERIMENTAL
Intervention: FI class 2 (0.21-0.31)
Number of subjects: 3881
Study 36341220 — intervention group
Group type: EXPERIMENTAL
Intervention: FI class 3 (>0.31)
Number of subjects: 3881
Study 36341220 — intervention group
Group type: COMPARATOR
Intervention: FI class 1 (<0.21, nonfrail)
Number of subjects: 3881
Study 36341220 — intervention group
Group type: EXPERIMENTAL
Intervention: FI class 2 (0.21-0.31) after multivariable adjustment
Number of subjects: 3881
Study 36341220 — intervention group
Group type: EXPERIMENTAL
Intervention: FI class 3 (>0.31) after multivariable adjustment
Number of subjects: 3881
Study 36341221 — intervention group
Group type: EXPERIMENTAL
Intervention: RD-AVR
Number of subjects: 1020
Study 36341221 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1020
Study 36341221 — intervention group
Group type: COMPARATOR
Intervention: TAVR
Number of subjects: 1020
Study 36341767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (investigator-assessed mRECIST)
Number of subjects: 0
Study 36341767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (IRR per mRECIST)
Number of subjects: 0
Study 36341767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (RECIST v1.1)
Number of subjects: 0
Study 36341767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (investigator-assessed mRECIST) at 2 months
Number of subjects: 0
Study 36341767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (investigator-assessed mRECIST) at 4 months
Number of subjects: 0
Study 36341767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (investigator-assessed mRECIST) at 6 months
Number of subjects: 0
Study 36341767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (multivariate Cox regression analysis)
Number of subjects: 0
Study 36342102 — intervention group
Group type: EXPERIMENTAL
Intervention: FS118 (800 μg to 0.3 mg/kg followed by 1 to 20 mg/kg weekly)
Number of subjects: 43
Study 36342102 — intervention group
Group type: EXPERIMENTAL
Intervention: FS118 (1 mg/kg or greater)
Number of subjects: 43
Study 36342102 — intervention group
Group type: EXPERIMENTAL
Intervention: FS118
Number of subjects: 43
Study 36342104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer/BioNTech BNT162b2 or Oxford/AstraZeneca ChAdOx1 vaccine; 99 patients received at least one dose of vaccine prior to, or during the study.
Number of subjects: 152
Study 36342104 — intervention group
Group type: COMPARATOR
Intervention: Control group (51 patients who did not receive a vaccination prior to, or during the study).
Number of subjects: 152
Study 36342109 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care algorithm to stratify patients with acute heart failure according to risk of death, leading to early discharge for low-risk patients (≤3 days) and admission for high-risk patients.
Number of subjects: 5452
Study 36342109 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control phase).
Number of subjects: 5452
Study 36342116 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg body weight)
Number of subjects: 1200
Study 36342116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 36342120 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1157
Study 36342120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study 36342173 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical revascularization in cohort 1
Number of subjects: 1830
Study 36342173 — intervention group
Group type: COMPARATOR
Intervention: Endovascular therapy in cohort 1
Number of subjects: 1830
Study 36342173 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical revascularization in cohort 2
Number of subjects: 1830
Study 36342173 — intervention group
Group type: COMPARATOR
Intervention: Endovascular therapy in cohort 2
Number of subjects: 1830
Study 36342269 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-detected TCFA
Number of subjects: 390
Study 36342269 — intervention group
Group type: COMPARATOR
Intervention: MACE group
Number of subjects: 390
Study 36342342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant abemaciclib combined with endocrine therapy (ET)
Number of subjects: 0
Study 36342343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg p.o.)
Number of subjects: 24
Study 36342343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36342421 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute mechanical circulatory support (AMCS)
Number of subjects: 1767
Study 36342421 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo HF-CS (DNHF-CS)
Number of subjects: 1767
Study 36342421 — intervention group
Group type: COMPARATOR
Intervention: Acute-on-chronic HF-CS
Number of subjects: 1767
Study 36342421 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital cardiac arrest
Number of subjects: 1767
Study 36342455 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA vaccination
Number of subjects: 0
Study 36342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study 36342619 — intervention group
Group type: COMPARATOR
Intervention: Eribulin
Number of subjects: 0
Study 36342619 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 0
Study 36342823 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification of primary care clinician and patient regarding incidental CAC, including a patient-specific image of CAC and guideline recommendations for statin use.
Number of subjects: 173
Study 36342823 — intervention group
Group type: COMPARATOR
Intervention: Usual care without notification.
Number of subjects: 173
Study 36342828 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital shared decision-making (SDM) toolkit including a brief animated video, interactive questions, a quiz, a worksheet, and an online guide for clinicians.
Number of subjects: 0
Study 36342828 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 36342853 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational extended-wear insulin infusion set (IIS)
Number of subjects: 6
Study 36342853 — intervention group
Group type: COMPARATOR
Intervention: Conventional Teflon angled insulin infusion set (IIS)
Number of subjects: 6
Study 36342912 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (two doses)
Number of subjects: 76
Study 36342912 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 36342964 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 36342964 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36342972 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic medications (ADMs) including biguanides (metformin), sulfonylureas (gliclazide, glibenclamide, glimepiride, glipizide, glyclopyramide), insulin (premix, basal, basal/bolus), DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin)
Number of subjects: 519
Study 36342972 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors
Number of subjects: 519
Study 36343360 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 12
Study 36343656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated preoperative radiotherapy (42.75 Gy in 15 fractions of 2.85 Gy/day for 3 weeks)
Number of subjects: 120
Study 36343656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated preoperative radiotherapy
Number of subjects: 120
Study 36343655 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic performance of the intervention (not specified in the abstract)
Number of subjects: 288
Study 36343674 — intervention group
Group type: COMPARATOR
Intervention: Active Crohn's disease (aCD)
Number of subjects: 60
Study 36343674 — intervention group
Group type: COMPARATOR
Intervention: Active ulcerative colitis (aUC)
Number of subjects: 60
Study 36343674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff values for rectal submucosa in CD
Number of subjects: 60
Study 36343674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff values for rectal mucosa in UC
Number of subjects: 60
Study 36343688 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood eosinophil count (BEC)
Number of subjects: 485
Study 36343688 — intervention group
Group type: COMPARATOR
Intervention: Low blood eosinophil count (BEC)
Number of subjects: 485
Study 36344555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear Transport Checkpoint Inhibitor (NTCI) topical treatment
Number of subjects: 0
Study 36344663 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h urinary Na/K ratio of approximately 2
Number of subjects: 1145
Study 36344663 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h urinary Na/K ratio range of 1.6‒2.2 for men
Number of subjects: 1145
Study 36344663 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h urinary Na/K ratio range of 1.7‒1.9 for women
Number of subjects: 1145
Study 36344663 — intervention group
Group type: EXPERIMENTAL
Intervention: Average molar ratio of 24 h urinary Na/K was 4.3
Number of subjects: 1145
Study 36344663 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate correlations (P < 0.001) of the 24 h urinary Na/K ratio with 24 h urinary Na and K excretion
Number of subjects: 1145
Study 36344663 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate correlation (P < 0.001) of the 24 h urinary Na/K ratio with dietary Na/K ratio
Number of subjects: 1145
Study 36344711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan (nal-IRI) at 70 mg/m² during HIPEC
Number of subjects: 18
Study 36344770 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 1450
Study 36344770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1450
Study 36344904 — intervention group
Group type: EXPERIMENTAL
Intervention: Male cancer survivors
Number of subjects: 305
Study 36344904 — intervention group
Group type: COMPARATOR
Intervention: Female cancer survivors
Number of subjects: 305
Study 36344904 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects aged 68 or older
Number of subjects: 305
Study 36344904 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 305
Study 36344924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg/kg
Number of subjects: 60
Study 36345016 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based mental health app used over five weeks
Number of subjects: 5
Study 36345016 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based mental health app
Number of subjects: 5
Study 36345143 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score < 15
Number of subjects: 2826
Study 36345143 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD-Na score < 20
Number of subjects: 2826
Study 36345143 — intervention group
Group type: COMPARATOR
Intervention: MELD score
Number of subjects: 2826
Study 36345143 — intervention group
Group type: COMPARATOR
Intervention: MELD-Na score
Number of subjects: 2826
Study 36345143 — intervention group
Group type: COMPARATOR
Intervention: MELD score ≥ 15
Number of subjects: 2826
Study 36345143 — intervention group
Group type: COMPARATOR
Intervention: MELD-Na score ≥ 20
Number of subjects: 2826
Study 36345253 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 40
Study 36345253 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 40
Study 36345253 — intervention group
Group type: COMPARATOR
Intervention: Nonobese volunteers
Number of subjects: 40
Study 36345941 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HIV duoCAR T cells
Number of subjects: 0
Study 36346005 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions (face-to-face or e-learning focusing on infective area, basic gestures, COVID clinical management and intensive care medicine)
Number of subjects: 37
Study 36346005 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions
Number of subjects: 37
Study 36346044 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and fluorouracil (infusional fluorouracil of 200 mg/m2)
Number of subjects: 0
Study 36346059 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding Academic Research Consortium 2, 3, or 5 bleeding
Number of subjects: 10364
Study 36346059 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding
Number of subjects: 10364
Study 36346059 — intervention group
Group type: EXPERIMENTAL
Intervention: Genitourinary bleeding
Number of subjects: 10364
Study 36346059 — intervention group
Group type: EXPERIMENTAL
Intervention: New gastrointestinal cancer diagnosis after gastrointestinal bleeding
Number of subjects: 10364
Study 36346059 — intervention group
Group type: EXPERIMENTAL
Intervention: New genitourinary cancer diagnosis after genitourinary bleeding
Number of subjects: 10364
Study 36346059 — intervention group
Group type: COMPARATOR
Intervention: New cancer diagnosis without previous bleeding
Number of subjects: 10364
Study 36346112 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use at baseline
Number of subjects: 1700
Study 36346112 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use at the start of maintenance therapy
Number of subjects: 1700
Study 36346112 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use at the start of maintenance cycle 4
Number of subjects: 1700
Study 36346112 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use at the start of maintenance treatment
Number of subjects: 1700
Study 36346118 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT with a positivity threshold of >15 mcg haemoglobin/g faeces, interval between rounds varied between 1.5 and 3.5 years
Number of subjects: 0
Study 36346229 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 60 mg administered orally
Number of subjects: 0
Study 36346366 — intervention group
Group type: EXPERIMENTAL
Intervention: ERK-MAPK inhibitor (ulixertinib) in combination with CDK4/6 inhibitor (palbociclib)
Number of subjects: 0
Study 36346366 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 loss-of-function screen
Number of subjects: 0
Study 36346366 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic combinations validated using siRNA and small-molecule inhibitors
Number of subjects: 0
Study 36346472 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected meal (SSM)
Number of subjects: 19
Study 36346679 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine (IM) intervention, single 30-minute session combining acupuncture, mind-body, and/or manual-movement modalities.
Number of subjects: 114
Study 36346687 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 658
Study 36346687 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 658
Study 36347049 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) treatment for 2 years
Number of subjects: 0
Study 36347049 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) treatment for 7 years
Number of subjects: 0
Study 36347128 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular techniques for treatment of ALI
Number of subjects: 0
Study 36347310 — intervention group
Group type: EXPERIMENTAL
Intervention: User-controlled sperm concentration test
Number of subjects: 38
Study 36347845 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg)
Number of subjects: 92
Study 36347863 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprosthesis using deep-learning and language-modeling techniques to decode letter sequences from silent attempts to spell
Number of subjects: 1
Study 36347863 — intervention group
Group type: EXPERIMENTAL
Intervention: Offline simulations of the neuroprosthesis
Number of subjects: 1
Study 36347900 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted partial nephrectomy (RPN)
Number of subjects: 2005
Study 36347900 — intervention group
Group type: COMPARATOR
Intervention: Open partial nephrectomy (OPN)
Number of subjects: 2005
Study 36348054 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h cough frequency measured using an ambulatory cough monitor
Number of subjects: 0
Study 36348054 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h cough frequency
Number of subjects: 0
Study 36348206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) using cisplatin with mitomycin C
Number of subjects: 41
Study 36348206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
Number of subjects: 41
Study 36348245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study 36348346 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive oncology clinical trial strategies implemented during the COVID-19 pandemic
Number of subjects: 0
Study 36348974 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system predicting MCI/mild AD
Number of subjects: 133
Study 36348974 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system predicting Aβ positivity
Number of subjects: 133
Study 36348974 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system predicting Aβ in MCI/mild AD subsample
Number of subjects: 133
Study 36348974 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system predicting Aβ in CU subsample
Number of subjects: 133
Study 36349057 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia group
Number of subjects: 149
Study 36349057 — intervention group
Group type: COMPARATOR
Intervention: Non-anemia group
Number of subjects: 149
Study 36349343 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFA-producing gut microbes
Number of subjects: 45
Study 36349343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal propionate
Number of subjects: 45
Study 36349343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal SCFAs
Number of subjects: 45
Study 36349343 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 45
Study 36349343 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin (HbA1c)
Number of subjects: 45
Study 36349343 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA and anthropometrics (BMI)
Number of subjects: 45
Study 36349793 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy
Number of subjects: 518
Study 36349793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid decliners
Number of subjects: 518
Study 36349793 — intervention group
Group type: COMPARATOR
Intervention: Non-rapid decliners
Number of subjects: 518
Study 36350017 — intervention group
Group type: EXPERIMENTAL
Intervention: M2SR 108 TCID50
Number of subjects: 0
Study 36350017 — intervention group
Group type: EXPERIMENTAL
Intervention: M2SR 109 TCID50
Number of subjects: 0
Study 36350017 — intervention group
Group type: EXPERIMENTAL
Intervention: M2SR
Number of subjects: 0
Study 36350017 — intervention group
Group type: COMPARATOR
Intervention: FluMist
Number of subjects: 0
Study 36350312 — intervention group
Group type: EXPERIMENTAL
Intervention: Molibresib 75 mg daily for MDS
Number of subjects: 111
Study 36350312 — intervention group
Group type: EXPERIMENTAL
Intervention: Molibresib 60 mg daily for CTCL
Number of subjects: 111
Study 36350312 — intervention group
Group type: EXPERIMENTAL
Intervention: Total study population with Molibresib
Number of subjects: 111
Study 36350359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake from supplements
Number of subjects: 265
Study 36350359 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of milk products
Number of subjects: 265
Study 36350359 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of meat products
Number of subjects: 265
Study 36350359 — intervention group
Group type: EXPERIMENTAL
Intervention: Travels to sunny countries
Number of subjects: 265
Study 36350359 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daylight time
Number of subjects: 265